CHRS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 116298 min ago

@ $2.65

Wydano: 14 vas. 2024 @ 20:49

Zwrot: -14.34%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: 0.62 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.52M
Średni wolumen	2.44M
Kapitalizacja rynkowa	257.64M
EPS	$0 ( 2024-03-13 )
Następna data zysków	( $-0.0500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.900
ATR14	$0.00500 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Erbez Georgia	Buy	54 000	Stock Option (Right to Buy)
2024-02-20	Erbez Georgia	Buy	0
2024-02-09	Wahlstrom Mats	Buy	99 988	Common Stock
2024-02-09	Wahlstrom Mats	Sell	99 988	Common Stock
2024-02-01	Wahlstrom Mats	Buy	44 991	Common Stock

INSIDER POWER
42.64
Last 94 transactions
Buy: 4 570 164 \| Sell: 1 886 237

Wolumen Korelacja

Długi: 0.23 (neutral)

Krótki: -0.73 (moderate negative)

Signal:(48.908) Neutral

Coherus BioSciences Inc Korelacja

10 Najbardziej pozytywne korelacje
STRA	0.91
AVID	0.906
KPTI	0.887
EGRX	0.884
PARA	0.883
PINC	0.877
COLM	0.873
MDWD	0.868
IVAC	0.866
KTCC	0.865

10 Najbardziej negatywne korelacje
MORF	-0.905
RXDX	-0.901
WPRT	-0.891
IMGN	-0.882
RESN	-0.875
MDWT	-0.872
FLMN	-0.871
ACOR	-0.866
ACVA	-0.861
IDCC	-0.857

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Coherus BioSciences Inc Korelacja - Waluta/Towar

0.24
( neutral )

0.11
( neutral )

0.00
( neutral )

0.03
( neutral )

Coherus BioSciences Inc Finanse

Annual	2023
Przychody:	$257.24M
Zysk brutto:	$94.46M (36.72 %)
EPS:	$-2.53

FY	2023
Przychody:	$257.24M
Zysk brutto:	$94.46M (36.72 %)
EPS:	$-2.53

FY	2022
Przychody:	$211.04M
Zysk brutto:	$140.96M (66.79 %)
EPS:	$-4.21

FY	2021
Przychody:	$326.55M
Zysk brutto:	$268.96M (82.36 %)
EPS:	$-3.63

Financial Reports:

No articles found.

Coherus BioSciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Aktualne aktualizacje dla Coherus BioSciences Inc [CHRS]

Upcoming Earnings Alert